Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Celgene Corporation
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
A long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn’s disease
To evaluate the long-term safety of oral GED-0301 in subjects with Crohn’s disease
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)
To compare the efficacy of lenalidomide versus placebo maintenance therapy
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
AN EARLY PHASE CLINICAL STUDY AT SEVERAL RESEARCH CENTERS TO EXPLORE THE SAFETY, BLOOD LEVELS AND ANTITUMOR EFFECTS USING DIFFERENT DOSES OF CC-115 TAKEN BY MOUTH FOR PATIENTS WITH ADVANCED SOLID CANCER OR EITHER NON-HODGKIN LYMPHOMA OR MULTIPLE MYELOMA. Ensayo clínico en fase inicial en varios centros de investigación para evaluar la seguridad, los niveles sanguíneos y efectos antitumorales usando distintas dosis de CC-115 administrado por vía oral a sujetos con tumores sólidos avanzados, linfoma no Hodgkin o mieloma múltiple
1. Determine the safety and tolerability of CC-115 when administered orally and to define the Non-Tolerated Dose and the Maximum Tolerated Dose. 2. Determine the PharmacoKinetics of CC-115. 1.De...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
Phase 3 study to evaluate safety and effectiveness of oral Apremilast (CC-10004) in patients with Psoriatic Arthritis
The primary objective of the study is to evaluate the clinical efficacy of 2 doses of apremilast (20 mg or 30 mg orally BID) compared with placebo, on the signs and symptoms of psoriatic arthritis (Ps...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
Phase 3 study to evaluate safety and effectiveness of oral Apremilast (CC-10004) in patients with Psoriatic Arthritis who have not been previously treated with disease-modifiying antirheumatic drugs
The primary objective of the study is to evaluate the clinical efficacy of 2 doses of apremilast (20 mg or 30 mg orally BID) compared with placebo, on the signs and symptoms of psoriatic arthritis (Ps...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
Investigation to Efficacy and Safety of CC-90001 in patients with Idiopathic Pulmonary Fibrosis
To evaluate the effect of CC-90001, 200 mg and 400 mg, when orally administered (PO) once daily (QD), compared with placebo, on percent of predicted forced vital capacity (FVC) after 24 weeks of tre...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
A study to evaluate the drug Mongersen (GED-0301) for the treatment of Crohn's disease in adults and adolescents
Evaluate efficacy of GED-0301 at Week 12, administered as either a single 160 mg tablet or as four 40 mg tablets, compared with placebo on clinical activity in subjects with active CD
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis
To evaluate the clinical efficacy of 2 doses of apremilast (20 mg or 30 mg orally twice per day [BID]), compared with placebo, on the signs and symptoms of psoriatic arthritis (PsA) after 24 weeks’ ad...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
A study to assess the safety, feasibility and clinical activity of JCAR015, a CAR-T cell therapy, in adults with B-cell acute lymphoblastic leukemia Un estudio que evalúa la seguridad, viabilidad y actividad clinica de JCAR015, una terapia celular de CAR-T, en adultos con leucemia linfoblástica aguda de células B
Cohorts 1 – 4: To evaluate the efficacy of JCAR015 as measured by overall remission rate (ORR) after the final JCAR015 infusion in subjects with morphologic evidence of disease, based on independent r...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Celgene Corporation
MAJ Il y a 5 ans
A clinical trial to compare the efficacy and safety of AG-221 (CC-90007) versus conventional treatment on older subjects with late stage acute myeloid leukemia harboring an Isocitrate Dehydrogenase 2 Mutation
To determine the primary efficacy, measured as overall survival (OS), of AG-221 compared with conventional care regimens (CCRs) in subjects 60 years or older with AML refractory to or relapsed after s...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
Suivant